Thromboembolic Findings in COVID-19 Autopsies: Pulmonary Thrombosis or Embolism?
Authors: Charuhas Deshpande
Journal: Annals of Internal Medicine (2020)

Editorials15 May 2020Thromboembolic Findings in COVID-19 Autopsies: Pulmonary Thrombosis or Embolism?FREECharuhas Deshpande, MDCharuhas Deshpande, MDUniversity of Pennsylvania, Philadelphia, Pennsylvania (C.D.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M20-3255 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) initially presented as pneumonia of unknown cause in Wuhan, China, in December 2019, and SARS-CoV-2 was identified as the causative agent in January 2020 (1). Since then COVID-19, with its pulmonary and other systemic manifestations, has spread globally—with more than 4.2 million cases and over 291 000 deaths in 187 countries reported (2). With spread of disease, abnormal coagulation variables with high incidence of venous thromboembolic (VTE) complications have been noted, raising the need to develop specific VTE diagnostic and therapeutic strategies (3).Complete autopsy studies were almost nonexistent in the initial phases of the outbreak; reasonably so, due to concerns related to infectivity, transmission rates, and biosafety. The few reports initially published were limited to postmortem biopsies in COVID-19–positive patients (4–6) or from lobectomy specimens initially resected for lung adenocarcinoma, but patients were later found to be COVID-19–positive (7). Pathologic features of exudative and proliferative phases of diffuse alveolar damage (DAD) were noted in these initial reports, and overlapping features with SARS were also noted. Later complete autopsies performed in the United States further supported the presence of DAD (8, 9).More recently, Wichmann and colleagues (10) reported the findings of 12 consecutive, legally mandated autopsies of patients with COVID-19. The authors noted a high incidence of pulmonary embolism with or without underlying deep venous thrombosis, despite the absence of history of VTE. Massive pulmonary embolism was the cause of death in one third of the cases, with an additional one fourth with recent deep venous thrombosis but without pulmonary embolism. Seventy-five percent were men, and two thirds of these were noted to have recent thrombosis in prostatic venous plexus. Preexisting coronary heart disease (50%), respiratory tract comorbidities, obesity, and type 2 diabetes mellitus were noted but an absence of antemortem VTEs. Histologically exudative phase DAD was noted in two thirds and presence of pulmonary thrombi in 5 out of 8 cases with DAD. Similar histologic findings of DAD with microthrombi in 45% of cases were also recently reported by Menter and associates in a series of 21 COVID-19–positive autopsies, 4 with prominent central pulmonary embolism (11).In this issue, Lax and colleagues (12) report the findings of autopsies performed on 11 patients randomly selected among 48 hospitalized COVID-19–positive decedents. Significant preexisting comorbid conditions included hypertension, type 2 diabetes mellitus, obesity, chronic obstructive pulmonary disease, coronary heart disease, cancer, as well as history of cerebrovascular disease (ischemic stroke in 4 patients) and pulmonary embolism (1 patient). After autopsy tissue fixation, grossly visible pulmonary thrombi were noted in all cases with associated infarcts in 9 out of these 11 (81%) autopsies. During their hospital stay, 10 of the 11 deceased patients had received prophylactic dose anticoagulant therapy, with 2 receiving this therapy even before admission, thus suggesting that pulmonary thrombi were formed despite anticoagulant therapy. Apart from DAD, histologic evaluation highlighted the presence of multiple thrombi in small to mid-sized pulmonary arteries with adjacent lung parenchymal infarcts.These autopsy studies highlight the importance of thromboembolic events in COVID-19. Wichmann and colleagues highlighted the high incidence of pulmonary embolism with or without deep venous thrombosis, as well as presence of recent thrombi in prostatic venous plexus, in patients with no history of VTE, suggesting de novo coagulopathy in these patients with COVID-19. In contrast, Lax and colleagues highlighted changes consistent with thrombosis occurring within the pulmonary arterial circulation, in the absence of apparent embolism.Microvascular thrombi can be seen in DAD (the histologic equivalent of adult respiratory distress syndrome or acute respiratory distress syndrome [ARDS]) with various causes, including sepsis, trauma, viral or mycoplasma pneumonia, aspiration, as well as toxic inhalation, as noted by Tomashefski (13). Thus, microvascular thrombosis is not a distinctive or diagnostic feature of lung parenchymal involvement in patients with COVID-19. Ultrastructural evidence of acute endothelial injury has also been demonstrated, regardless of and without correlation with the cause of ARDS. Macrothrombi (thrombi in arteries with internal diameter >1 mm), large microthrombi, and capillary microthrombi have also been reported in patients with ARDS, due to other causes listed above. Pulmonary infarcts are also seen in patients with ARDS who died sooner (10 to 19 days) and later (≥20 days) after intubation (13). Taken together, prior reports and more recent descriptions of DAD in COVID-19 suggest that these microscopic findings are not specific to the etiology, but rather a general feature of acute lung injury at various stages of response to injury.The contributions of pulmonary thrombosis, embolism, or their combination to deaths of patients with COVID-19 may remain unaddressed because of the limited number of autopsy studies available. Although histologic or ultrastructural-level morphologic differences may not be evident, pathogen-specific molecular or immunologic differences may contribute to the different scenarios suggested in the current studies. To more thoroughly assess these questions will require tissues obtained either as postmortem biopsies or as complete autopsies. Further, appropriately stored tissues may be used in future studies to assess not only the underlying pathogenesis but also to inform the development of diagnostic biomarkers and clinical trials of therapeutic strategies aiming to better equip us for the next pathogen, epidemic, or even pandemic.References1. Zhu N, Zhang D, Wang W, et al; China Novel Coronavirus Investigating and Research Team. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733. [PMID: 31978945] doi:10.1056/NEJMoa2001017 CrossrefMedlineGoogle Scholar2. COVID-19 Map—Johns Hopkins Coronavirus Resource Center. Accessed at https://coronavirus.jhu.edu/map.html on 12 May 2020. Google Scholar3. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18:1023-1026. [PMID: 32338827] doi:10.1111/jth.14810 CrossrefMedlineGoogle Scholar4. Tian S, Xiong Y, Liu H, et al. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020. [PMID: 32291399] doi:10.1038/s41379-020-0536-x CrossrefMedlineGoogle Scholar5. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420-422. [PMID: 32085846] doi:10.1016/S2213-2600(20)30076-X CrossrefMedlineGoogle Scholar6. Zhang H, Zhou P, Wei Y, et al. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19 [Letter]. Ann Intern Med. 2020;172:629-632. [PMID: 32163542]. doi:10.7326/M20-0533 LinkGoogle Scholar7. Tian S, Hu W, Niu L, et al. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15:700-704. [PMID: 32114094] doi:10.1016/j.jtho.2020.02.010 CrossrefMedlineGoogle Scholar8. Barton LM, Duval EJ, Stroberg E, et al. COVID-19 autopsies, Oklahoma, USA. Am J Clin Pathol. 2020;153:725-733. [PMID: 32275742] doi:10.1093/ajcp/aqaa062 CrossrefMedlineGoogle Scholar9. Konopka KE, Wilson A, Myers JL. Postmortem lung findings in an asthmatic patient with coronavirus disease 2019. Chest. 2020. [PMID: 32360729] doi:10.1016/j.chest.2020.04.032 CrossrefMedlineGoogle Scholar10. Wichmann D, Sperhake JP, Lütgehetmann M, et al. Autopsy findings and venous thromboembolism in patients with COVID-19. A prospective cohort study. Ann Intern Med. 2020;173:268-77. [PMID: 32374815]. doi:10.7326/M20-2003 LinkGoogle Scholar11. Menter T, Haslbauer JD, Nienhold R, et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020. [PMID: 32364264] doi:10.1111/his.14134 CrossrefMedlineGoogle Scholar12. Lax SF, Skok K, Zechner P, et al. Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series. Ann Intern Med. 2020;173:350-61. [PMID: 32422076]. doi:10.7326/M20-2566 LinkGoogle Scholar13. Tomashefski JF. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med. 2000;21:435-66. [PMID: 11019719] CrossrefMedlineGoogle Scholar Comments 0 Comments Sign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Charuhas Deshpande, MDAffiliations: University of Pennsylvania, Philadelphia, Pennsylvania (C.D.)Disclosures: The author has disclosed no conflicts of interest. His form can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-3255.Corresponding Author: Charuhas Deshpande, MD, Associate Professor, Clinical Pathology and Laboratory Medicine, University of Pennsylvania, Founder 6.039, 3400 Spruce Street, Philadelphia, PA 19104; e-mail, Charuhas.Deshpande@pennmedicine.upenn.edu.This article was published at Annals.org on 14 May 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome Sigurd F. Lax , Kristijan Skok , Peter Zechner , Harald H. Kessler , Norbert Kaufmann , Camillo Koelblinger , Klaus Vander , Ute Bargfrieder , and Michael Trauner Metrics Cited byPyroptosis: a double-edged sword in lung cancer and other respiratory diseasesInsight to Combat Post COVID-19 Mortality: Complications and their BiomarkersA Pictorial Essay Describing the CT Imaging Features of COVID-19 Cases throughout the Pandemic with a Special Focus on Lung Manifestations and Extrapulmonary Vascular Abdominal ComplicationsRespiratory Failure in COVID-19 ConditionPoint-of-care echocardiography and thoracic ultrasound in the management of critically ill patients with COVID-19 infection: Experience in three regional UK intensive care unitsDevelopment of herd protection in older people in the context of universal COVID-19 vaccinationA urinary proteomic landscape of COVID-19 progression identifies signaling pathways and therapeutic optionsFatal pulmonary thromboembolism in asymptomatic COVID-19Tromboembolismo pulmonar durante la pandemia por SARS-CoV-2: características clínicas y radiológicasPulmonary embolism during SARS-CoV-2 pandemic: Clinical and radiological featuresAcute Pulmonary Embolism in COVID-19: A Potential Connection between Venous Congestion and Thrombus DistributionCOVID-19 Hurricane: Recovering the Worldwide Health System with the RE.RE.RE. (REsponse–REstoration–REengineering) Approach—Who Will Get There First?Pulmonary Embolism (PE) Prevalence in Mexican-Mestizo Patients With Severe SARS-COV-2 (COVID-19) Pneumonia At A Tertiary-Level Hospital: A ReviewCytokine storm and histopathological findings in 60 cases of COVID-19-related death: from viral load research to immunohistochemical quantification of major players IL-1β, IL-6, IL-15 and TNF-αAnatomical and Pathological Observation and Analysis of SARS and COVID-19: Microthrombosis Is the Main Cause of DeathRecent omics-based computational methods for COVID-19 drug discovery and repurposingInflammasome activation at the crux of severe COVID-19Pulmonary embolism in patients with COVID-19 pneumonia: When we have to search for it?Histopathological findings and clinicopathologic correlation in COVID-19: a systematic reviewMesenchymal Stem Cell-Based Therapy as an Alternative to the Treatment of Acute Respiratory Distress Syndrome: Current Evidence and Future PerspectivesCOVID-19: A HEALTH PERSPECTIVEClinical complications seen in patients after recovery from coronavirus disease 2019: Experience from a COVID care centerAlveolar hemorrhage in the setting of COVID-19: Report of a successful vascular intervention and embolizationHistopathologic Evaluation of COVID-19 Patients With Peripheral Arterial Thromboembolism: Does Clot Composition Make Any Sense?Influence of thromboembolic events in the prognosis of COVID-19 hospitalized patients. Results from a cross sectional studyPulmonary thrombosis in Covid-19: before, during and after hospital admissionQualitative and quantitative DECT pulmonary angiography in COVID-19 pneumonia and pulmonary embolismTherapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trialDelayed manifestation of extensive COVID-19-associated coagulopathy in high-risk patientRecent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19Pulmonary Endothelial Dysfunction and Thrombotic Complications in Patients with COVID-19Vascular Abnormalities Detected with Chest CT in COVID-19: Spectrum, Association with Parenchymal Lesions, Cardiac Changes, and Correlation with Clinical Severity (COVID-CAVA Study)Nanotechnology to the Rescue: Treatment Perspective for the Immune Dysregulation Observed in COVID-19Gross, Histopathological, and Ultrastructural Features in Patients with COVID-19: A Literature ReviewAngiotensin-converting enzyme 2 and COVID-19: patients, comorbidities, and therapiesPre-admission anti-coagulation does not improve all-cause mortality in geriatric COVID-19 patientsA Descriptive and Quantitative Immunohistochemical Study Demonstrating a Spectrum of Platelet Recruitment Patterns Across Pulmonary Infections Including COVID-19Plasma exchange in the treatment of complex COVID-19-related critical illness: controversies and perspectivesUse of Chest Imaging in the Diagnosis and Management of COVID-19: A WHO Rapid Advice GuideSystematic Screening for Deep Vein Thrombosis in Critically Ill Inpatients With COVID-19: Impact on the Incidence of Venous ThromboembolismLow ADAMTS13 Activity Correlates with Increased Mortality in COVID-19 PatientsExtreme phenotypes approach to investigate host genetics and COVID-19 outcomesRecent Advancements on COVID-19: A Comprehensive ReviewCoagulative Disorders in Critically Ill COVID-19 Patients with Acute Distress Respiratory Syndrome: A Critical ReviewReply to Rappaport et al. : Anti-FXa Activity with Intermediate-Dose Thromboprophylaxis in COVID-19Potential Mechanisms for Traditional Chinese Medicine in Treating Airway Mucus Hypersecretion Associated With Coronavirus Disease 2019A higher D-dimer threshold for predicting pulmonary embolism in patients with COVID-19: a retrospective studyTocilizumab in the treatment of rapidly evolving COVID-19 pneumonia and multifaceted critical illness: A retrospective case seriesCOVID-19 detection in radiological text reports integrating entity recognitionReverse takotsubo cardiomyopathy in fulminant COVID-19 associated with cytokine release syndrome and resolution following therapeutic plasma exchange: a case-reportPeripheral neuropathy in severe COVID‐19 resolved with therapeutic plasma exchangeLongitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19Rare case of COVID-19 presenting as acute abdomen and sepsisMesenchymal Stem Cells and Their Extracellular Vesicles: A Potential Game Changer for the COVID-19 CrisisPulmonary arterial thrombosis as an important complication of COVID-19 pulmonary disease: letter to the editorPreliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 PatientsFragile Endothelium and Brain Dysregulated Neurochemical Activity in COVID-19Pulmonary Embolism at CT Pulmonary Angiography in Patients with COVID-19Thromboembolic events and Covid-19Extrapulmonary manifestations of COVID-19Insidious development of pulmonary embolism in asymptomatic patients with COVID-19: Two rare case-reportsLife-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series 1 September 2020Volume 173, Issue 5 Page: 394-395 Keywords Acute respiratory distress syndrome Anticoagulant therapy Autopsy COVID-19 Deep vein thrombosis Lungs Pneumonia Pulmonary embolism Thrombosis Type 2 diabetes ePublished: 15 May 2020 Issue Published: 1 September 2020 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...